Manufacturing News and Research

RSS
MOVANTIK (naloxegol) now available in U.S. for treatment of OIC in adult patients with non-cancer pain

MOVANTIK (naloxegol) now available in U.S. for treatment of OIC in adult patients with non-cancer pain

IDT supports unique bioengineering public outreach program

IDT supports unique bioengineering public outreach program

China Pharma's revenue decreases 24% to $24.9 million in fiscal year 2014

China Pharma's revenue decreases 24% to $24.9 million in fiscal year 2014

Investigational S-equol nutritional supplement may alleviate certain menopause symptoms

Investigational S-equol nutritional supplement may alleviate certain menopause symptoms

VUEMED to deploy Impinj xArray technology for tracking and managing medical devices

VUEMED to deploy Impinj xArray technology for tracking and managing medical devices

MTI Expo 2015 to focus on engineering requirements in the medical technology sector

MTI Expo 2015 to focus on engineering requirements in the medical technology sector

CFDA accepts WuXi MedImmune's novel anti-IL6 monoclonal antibody IND application for review

CFDA accepts WuXi MedImmune's novel anti-IL6 monoclonal antibody IND application for review

Philips enters into collaboration with Janssen to develop new handheld blood test to support care of patients with neuropsychiatric disorders

Philips enters into collaboration with Janssen to develop new handheld blood test to support care of patients with neuropsychiatric disorders

Cellworld 2015 conference to be held in Downtown San Francisco  on Sept. 21-22, 2015

Cellworld 2015 conference to be held in Downtown San Francisco on Sept. 21-22, 2015

Brainstorm Cell Therapeutics provides business update, announces financial results for 2014

Brainstorm Cell Therapeutics provides business update, announces financial results for 2014

C3BS plans to open new U.S.-based facility to manufacture C-Cure for use in Phase III trial

C3BS plans to open new U.S.-based facility to manufacture C-Cure for use in Phase III trial

Novasep, Celladon sign agreement to develop and supply MYDICAR drug substance

Novasep, Celladon sign agreement to develop and supply MYDICAR drug substance

Theravectys gets authorization to produce lentiviral vectors for clinical use and CAR-T cell-based immunotherapy

Theravectys gets authorization to produce lentiviral vectors for clinical use and CAR-T cell-based immunotherapy

Sun Pharma closes Ranbaxy merger

Sun Pharma closes Ranbaxy merger

Marken secures Best Life Science Logistics Provider award

Marken secures Best Life Science Logistics Provider award

Egalet announces plans to commercialize SPRIX Nasal Spray and OXAYDO tablets

Egalet announces plans to commercialize SPRIX Nasal Spray and OXAYDO tablets

Immunomagnetic assay with microfluidic technology can capture, manipulate circulating tumor cells

Immunomagnetic assay with microfluidic technology can capture, manipulate circulating tumor cells

Dipexium Pharmaceuticals reports strong financial results for year ended December 31, 2014

Dipexium Pharmaceuticals reports strong financial results for year ended December 31, 2014

GenVec collaborates with TheraBiologics to develop NSC-mediated cancer therapeutics

GenVec collaborates with TheraBiologics to develop NSC-mediated cancer therapeutics

MEDITE announces granting of German priority patent for Histology 'Lab-in-one Automation' System

MEDITE announces granting of German priority patent for Histology 'Lab-in-one Automation' System

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.